fexofenadine hydrochloride

(redirected from Allegra ODT)

fexofenadine hydrochloride

Allegra, Allegra ODT, Telfast (UK)

Pharmacologic class: Peripherally selective piperidine, selective histamine1-receptor antagonist

Therapeutic class: Antihistamine (nonsedating type), second-generation

Pregnancy risk category C

Action

Blocks effects of histamine at peripheral histamine1-receptor sites, decreasing allergy signs and symptoms

Availability

Capsules: 60 mg

Oral suspension: 30 mg/5 ml (6 mg/ml)

Tablets: 30 mg, 60 mg, 180 mg

Tablets (orally disintegrating): 30 mg

Indications and dosages

Seasonal allergic rhinitis; chronic idiopathic urticaria

Adults and children age 12 and older: 60 mg P.O. b.i.d. or 180 mg once daily (conventional tablets)

Children ages 6 to 11: 30 mg P.O. b.i.d. (conventional tablets or ODT tablets)

Seasonal allergic rhinitis

Children ages 2 to 11: 30 mg P.O. b.i.d. (oral suspension and ODT)

Chronic idiopathic urticaria

Children ages 6 months to less than 2 years: 15 mg P.O. b.i.d.(oral suspension and ODT)

Dosage adjustment

• Renal impairment

Contraindications

• Hypersensitivity to drug, terfenadine, or their components

Precautions

Use cautiously in:

• renal impairment

• concurrent ketoconazole or erythromycin therapy

• elderly patients

• pregnant or breastfeeding patients.

Administration

• Give capsules and conventional tablets with water; don't give with apple, orange, or grapefruit juice.

• Don't remove orally disintegrating tablets from original blister package until time of administration.

• Administer orally disintegrating tablets on an empty stomach; allow tablets to disintegrate on the tongue and then have patient swallow tablets with or without water.

• Don't break or use partial orally disintegrating tablets

• Know that orally disintegrating tablets contain phenylalanine.

• Don't give antacids within 2 hours of fexofenadine.

Adverse reactions

CNS: drowsiness, fatigue, headache

EENT: otitis media

GI: nausea, dyspepsia

Metabolic: dysmenorrhea

Respiratory: upper respiratory tract infection

Other: viral infection

Interactions

Drug-drug. Antacids containing aluminum and magnesium: decreased absorption and efficacy of fexofenadine

Drug-diagnostic tests. Skin allergy tests: false-negative results

Drug-food. Apple, orange, and grapefruit juice: decreased absorption and efficacy of fexofenadine

Patient monitoring

• Monitor renal function.

• Watch for signs and symptoms of viral infection.

Patient teaching

• Instruct patient to take conventional tablets with water, and not with apple, orange, or grapefruit juice.

• Instruct patient not to remove orally disintegrating tablets from original blister package until time of administration.

• Instruct patient to take orally disintegrating tablets on an empty stomach at least 1 hour before or 2 hours after a meal, to allow tablet to disintegrate on the tongue, and then to swallow with or without water. Advise patient not to chew tablets.

• Tell patient not to break or use partial orally disintegrating tablets.

• Tell patient to stop taking drug 4 days before diagnostic skin tests, to avoid interference with test results.

• Advise patient to report signs or symptoms of viral infection, especially upper respiratory tract infection.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• Advise female patient to inform prescriber if she is pregnant or breastfeeding.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

Mentioned in ?
References in periodicals archive ?
Allegra ODT (fexofenadine HCI orally disintegrating tablet, 30 mg, Sanofi Aventis)
The FDA approved Allegra ODT, 30 mg, for relief of symptoms of seasonal allergic rhinitis and for the treatment of un complicated skin manifestations of chronic idiopathic urticaria (hives) for children aged 6-11 years.
Allegra ODT (fexofenadine HCl orally disintegrating tablet, 30 rag, Sanofi Aventis)
The FDA approved Allegra ODT, 30 mg, for relief of symptoms of seasonal allergic rhinitis and for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (hives) for children aged 6-11 years.